TABLE 3.
Sensitivity Analysis of Boundary Inclusion at ≥90 mg
| Definition | Patients >90 Daily MME, n (%) | Patients ≥90 Daily MME, n (%) | Rate Difference Per 1000 (95% CI) | Number Needed to Harm* |
|---|---|---|---|---|
| California | ||||
| Total days supply | 87,078 (3.6) | 106,240 (4.4) | 7.9 (7.5, 8.2) | 1 in 127 |
| On-therapy days | 140,822 (5.8) | 155,254 (6.4) | 5.9 (5.5, 6.4) | 1 in 169 |
| Fixed observation window | 86,407 (3.6) | 87,407 (3.6) | 0.41 (0.07, 0.75) | 1 in 2430 |
| Maximum daily dose | 249,471 (10.3) | 285,807 (11.8) | 15.0 (14.3, 15.5) | 1 in 67 |
| Total adult opioid patients | 2,430,870 | |||
| Florida | ||||
| Total days supply | 87,295 (5.9) | 113,998 (7.7) | 18.0 (17.4, 18.6) | 1 in 56 |
| On-therapy days | 136,995 (9.2) | 157,794 (10.6) | 14.0 (13.3, 14.7) | 1 in 72 |
| Fixed observation window | 97,346 (6.6) | 98,541 (6.6) | 0.80 (0.22, 1.4) | 1 in 1244 |
| Maximum daily dose | 211,429 (14.2) | 261,335 (17.6) | 33.6 (32.7, 34.5) | 1 in 30 |
| Total adult opioid patients | 1,485,591 | |||
*
Number of patients seen before one would be misclassified as “low dose” who should have been considered “high dose” by using 90 mg instead of 91 mg as a threshold.
CI indicates confidence interval; MME, milligrams of morphine equivalents.